（一）独立董事人员变更情况 截至 2024 年 12 月 31 日，公司第三届董事会由 9 名董事组成，其中独立董事 3 名，占董事人数的三分之一，符合法律法规的相关规定。 北京佰仁医疗科技股份有限公司 独立董事 2024 年度述职报告（曹贤智） 本人为经公司 2024 年第一次临时股东大会选举担任第三届董事会独立董事， 现将 2024 年度履职情况报告如下： 一、公司独立董事的基本情况 作为北京佰仁医疗科技股份有限公司（以下简称"公司"）的第三届董事会独立 董事，2024 年本人严格根据《中华人民共和国公司法》（以下简称"《公司法》"）、 《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监 管指引第 1 号——规范运作》《上市公司独立董事管理办法》等法律法规、规章和 规范性文件以及《北京佰仁医疗科技股份有限公司章程》（以下简称"《公司章程》"） 和《北京佰仁医疗科技股份有限公司独立董事工作制度》的有关规定和要求，秉 持客观、独立、公正的立场，诚实、勤勉、独立地履行职责，积极出席相关会议， 独立自主决策，充分发挥独立董事及各专门委员会的作用，切实维护公司和全体 股东特别是中小股东的合法权 ...

北京佰仁医疗科技股份有限公司 独立董事 2024 年度述职报告（吴信） 作为北京佰仁医疗科技股份有限公司（以下简称"公司"）第二届董事会独立董 事，2024 年本人严格根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上 海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公司自律监管指 引第 1 号——规范运作》《上市公司独立董事管理办法》等法律法规、规章和规范 性文件以及《北京佰仁医疗科技股份有限公司章程》（以下简称"《公司章程》"） 和《北京佰仁医疗科技股份有限公司独立董事工作制度》的有关规定和要求，秉 持客观、独立、公正的立场，诚实、勤勉、独立地履行职责，积极出席相关会议， 独立自主决策，充分发挥独立董事及各专门委员会的作用，切实维护公司和全体 股东特别是中小股东的合法权益，促进了公司规范运作。 本人因任期届满，于 2024 年 1 月 31 日公司召开 2024 年第一次临时股东大会 选举产生新任独立董事后正式离任，不再担任公司董事会独立董事及各专门委员 会中的相关职务。现将本人在 2024 年度任职期间履行独立董事职责的情况报告如 下： 一、公司独立董事的基本情况 （一）独立董事人员 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of RMB 1.2 billion for the fiscal year, representing a 25% year-over-year growth[15]. - The company's operating revenue for 2024 reached CNY 501,879,121.74, representing a year-on-year increase of 35.41% compared to CNY 370,638,328.12 in 2023[22]. - Net profit attributable to shareholders for 2024 was CNY 146,330,147.71, up 27.02% from CNY 115,206,553.74 in 2023[22]. - The company achieved a net profit margin of approximately 32.39% after excluding the impact of share-based payments, with a net profit of CNY 162,539,400 in 2024[26]. - Revenue growth for the reporting period was 35.41%, successfully achieving the annual sales target despite a challenging market environment[38]. - The company’s revenue from the heart valve replacement and repair segment grew by 64.28% year-on-year[141]. - The company reported a net cash outflow from investment activities of RMB -276,231,153.13, primarily due to increased cash payments for long-term asset acquisitions[136]. - The company generated CNY 136,231,273.41 in net cash flow from operating activities, a decrease of 3.50% year-on-year[156]. Research and Development - Research and development expenses increased by 18%, totaling RMB 200 million, to support innovation in medical technologies[15]. - Research and development expenses for 2024 amounted to CNY 15,144,190, a 53.26% increase year-on-year, accounting for 30.17% of operating revenue[25]. - The company is actively enhancing its research capabilities by investing in various laboratories and recruiting top talent[43]. - The company is focusing on the development of innovative products in the minimally invasive myocardial resection system, with clinical trials progressing smoothly[43]. - The company has received approval for 21 Class III medical device products, with 10 of them filling domestic market gaps, showcasing its innovation capabilities[40]. - The company has developed a new "transcatheter aortic valve system," which was approved for registration in August 2024[115]. - R&D investment accounted for 30.17% of the company's revenue during the reporting period, indicating a strong commitment to innovation despite the inherent risks of product development[126]. Market Expansion and Strategy - The company is expanding its market presence in Southeast Asia, targeting a 10% increase in market penetration by the end of the next fiscal year[15]. - A strategic acquisition of a smaller competitor was completed, which is anticipated to enhance the company's product offerings and increase market share by 5%[15]. - The company plans to implement a new sales strategy aimed at increasing direct-to-consumer sales by 25% over the next year[15]. - The company is committed to expanding its market presence and product offerings in response to evolving regulatory and market conditions, ensuring sustainable growth[66]. - The company is focusing on the development of high-end implantable products, including new types of medical imaging, stent valves, and artificial joints, as part of its strategic initiatives[66]. - The company is exploring new strategies for market expansion through innovative product registrations and technological advancements in the cardiovascular sector[112]. Corporate Governance - The company emphasizes the importance of accurate and complete information disclosure, adhering to legal regulations and internal control systems, ensuring no insider information leaks occurred during the reporting period[181]. - The board of directors and independent directors actively participated in decision-making, with no objections raised during board meetings, indicating a unified governance approach[180]. - The company has established and continuously improved internal control governance systems, including key management regulations, to ensure compliance with legal requirements[180]. - The company plans to enhance its corporate governance structure and internal control mechanisms to promote sustainable development in the future[182]. - The company has implemented measures to address any potential conflicts of interest with controlling shareholders, maintaining operational independence[182]. - The company is committed to regular internal control self-evaluations to ensure compliance with governance requirements[180]. Product Development and Innovation - The company launched several new products, including the TAVR 2.0 system, contributing to a significant increase in sales revenue across all three business segments, with heart valve replacement and repair segment growing by 64.28%[24]. - The company is actively pursuing clinical trials for multiple innovative products, with significant progress reported in the "minimally invasive myocardial resection system" clinical trial[25]. - The company is developing a comprehensive solution for valve disease treatment, focusing on a full lifecycle management approach[52]. - The company is committed to providing solutions for complex congenital heart diseases, including the complex congenital single-leaflet patch[52]. - The company has developed innovative products such as the RenatusTM transcatheter aortic valve system, which features a patented sewing technique and has demonstrated comparable durability to surgical bioprosthetic valves[75]. - The company is focusing on expanding its product offerings in the field of minimally invasive cardiac interventions, with a total investment of 929.52 million in micro-invasive techniques[112]. Financial Management - The company plans to distribute a cash dividend of 8.00 CNY per 10 shares, totaling approximately 109.92 million CNY, which represents 75.12% of the net profit attributable to the parent company[5]. - The total share capital as of December 31, 2024, is 137,395,148 shares[5]. - The company has not reported any non-operating fund occupation by controlling shareholders or related parties[8]. - The company has not experienced any instances where more than half of the board members could not guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has not conducted any capital reserve transfers to increase share capital or issued bonus shares for the year[5]. - The company has reduced share-based payment expenses due to a decrease in the number of shares attributed, contributing to the changes in non-IFRS financial indicators[34]. Operational Efficiency - The company reported a gross margin of 60%, reflecting improved operational efficiency compared to the previous year[15]. - The company’s sales expenses accounted for 21.83% of operating income, remaining stable during the reporting period[41]. - The company is committed to improving product quality and production efficiency while controlling production costs amid expanding product lines[45]. - The company is addressing the challenges of multi-product and material expansion by optimizing process management[45]. - The company has established a stable production management team, with extensive experience in the manufacturing process of biological valves, ensuring product quality and safety[125]. Regulatory Compliance and Risks - The company faces risks related to regulatory compliance, particularly for Class III implantable medical devices, which require stringent quality control and oversight[130]. - The implementation of national policies on high-value medical consumables, such as volume-based procurement, poses potential risks to the company's sales revenue if it fails to secure expected market shares[131]. - The company has not been subject to penalties from securities regulatory agencies in the past three years[200].

Financial Performance - The company's operating revenue for Q1 2025 reached ¥100,139,512.37, representing a year-on-year increase of 31.30% compared to ¥76,265,199.91 in the same period last year[3] - Net profit attributable to shareholders was ¥32,504,318.17, a significant increase of 290.69% from ¥8,319,805.58 in the previous year[3] - The net profit after deducting non-recurring gains and losses was ¥23,058,724.48, reflecting a year-on-year growth of 261.55%[3] - Basic and diluted earnings per share increased to ¥0.24, marking a 300.00% rise from ¥0.06 in the previous year[3] - Net profit for Q1 2025 was ¥30,182,278.65, significantly up from ¥3,896,260.45 in Q1 2024, marking an increase of 674.5%[16] - Earnings per share for Q1 2025 was ¥0.24, compared to ¥0.06 in Q1 2024, indicating a substantial growth in profitability[16] Cash Flow - The cash flow from operating activities turned positive with a net amount of ¥9,377,543.59, compared to a negative cash flow of ¥9,996,863.18 in the same period last year[3] - In Q1 2025, the company reported cash inflows from operating activities of ¥138,071,172.98, a 60.5% increase compared to ¥85,945,909.70 in Q1 2024[17] - The net cash flow from operating activities for Q1 2025 was ¥9,377,543.59, recovering from a negative cash flow of ¥9,996,863.18 in Q1 2024[17] - The company generated cash inflows from investment activities amounting to ¥209,828,995.77 in Q1 2025, compared to ¥351,769,091.11 in Q1 2024, reflecting a decrease of 40.2%[18] - The net cash flow from investment activities improved to ¥11,028,377.93 in Q1 2025, compared to a negative cash flow of ¥24,368,707.16 in Q1 2024[18] - Cash inflows from financing activities totaled ¥25,000,000.00 in Q1 2025, with a net cash flow of ¥23,850,093.74, recovering from a negative cash flow of ¥1,110,924.96 in Q1 2024[18] - The company's cash and cash equivalents increased by ¥44,199,977.74 in Q1 2025, compared to a decrease of ¥35,472,099.71 in Q1 2024[18] - The ending balance of cash and cash equivalents for Q1 2025 was ¥99,749,784.99, up from ¥259,104,030.78 in Q1 2024[18] Research and Development - Research and development expenses totaled ¥33,115,530.01, which is a decrease of 17.44% compared to ¥40,109,397.09 in the same period last year[4] - The proportion of R&D expenses to operating revenue decreased to 33.07%, down by 19.52 percentage points from 52.59% year-on-year[4] Assets and Liabilities - Total assets at the end of the reporting period were ¥1,473,322,628.78, an increase of 2.97% from ¥1,430,847,757.81 at the end of the previous year[4] - Total current assets as of March 31, 2025, amount to ¥627,974,165.38, an increase from ¥590,807,691.95 as of December 31, 2024[11] - Total liabilities rose to ¥190,547,577.12, compared to ¥180,277,337.07 in the previous period, reflecting an increase of 1.4%[13] - Non-current assets totaled ¥845,348,463.40, slightly up from ¥840,040,065.86, indicating stability in long-term investments[12] - The company reported a decrease in accounts payable from ¥66,464,107.44 to ¥54,440,177.50, a reduction of 18%[12] Market Position and Future Outlook - The company has maintained a strong market presence with approximately 60% market share in the field of surgical heart valve replacement and repair products, driven by the acceleration of domestic product replacements[4] - The company is advancing multiple clinical trials and has submitted registrations for new products, which are expected to enhance future profitability[4] Shareholder Information - Total number of common shareholders at the end of the reporting period is 3,099[9] - The largest shareholder, Jin Lei, holds 84,096,851 shares, representing 61.21% of total shares[10] Other Information - The company has no significant changes in the top 10 shareholders due to securities lending[11] - The company has not reported any new strategies or product developments during the conference call[11] - There are no significant reminders for investors regarding the company's operational status during the reporting period[11]

一、关于独立董事独立性的自查情况 北京佰仁医疗科技股份有限公司（以下简称"公司"）现有独立董事 3 人， 分别为周 正先生、刘浩先生、曹贤智先生。根据《上市公司独立董事管理办法》等相关规定， 公司独立董事对自身的独立性情况进行了自查，并将自查情况提交至公司董事会。自查 结果显示，公司独立董事均符合《上市公司独立董事管理办法》所规定的独立性要求， 与公司及其主要股东、实际控制人不存在直接或者间接利害关系，或者其他可能影响其 进行独立客观判断关系的情形，能够独立履行职责，不受公司及其主要股东、实际控制 人等单位或者个人的影响。 北京佰仁医疗科技股份有限公司董事会 对独立董事独立性自查情况的专项报告 二、公司董事会对独立董事独立性自查情况的评估意见 经核查公司现任独立董事周正先生、刘浩先生、曹贤智先生的任职经历及其提交的 自查报告，董事会认为：上述独立董事未在公司担任除独立董事及董事会专门委员会委 员以外的任何职务，亦未在公司的主要股东单位中担任任何职务，与公司及其主要股东 之间不存在任何形式的利益冲突、关联关系或其他可能对其独立客观判断产生影响的情 况；符合《上市公司独立董事管理办法》《上海证券交易所科创板上市公 ...

北京佰仁医疗科技股份有限公司 董事会审计委员会 2024 年度履职情况报告 公司董事会： 北京佰仁医疗科技股份有限公司（以下简称"公司"）董事会审计委员会根据《上市 公司治理准则》《上海证券交易所科创板股票上市规则》《上海证券交易所科创板上市公 司自律监管指引第 1 号—规范运作》以及《北京佰仁医疗科技股份有限公司章程》（以 下简称"《公司章程》"）、《北京佰仁医疗科技股份有限公司董事会审计委员会实施细则》 等相关规定，本着勤勉尽责的原则，认真履行审计监督职责，现对 2024 年度的履职情 况汇报如下： 一、董事会审计委员会基本情况 公司董事会审计委员会由董事曹贤智先生、周正先生、金森先生组成，其中独立董 事 2 名，审计委员会主任委员由具有专业会计资格的独立董事曹贤智先生担任。 二、董事会审计委员会 2024 年度会议召开情况 2024 年度，公司董事会审计委员会共召开了 6 次会议： 1、2024 年 1 月 31 日，公司召开第二届董事会审计委员会 2024 年第一次例会会议， 审议通过了《关于聘任公司财务总监的议案》《关于制定<公司会计师事务所选聘制度> 的议案》，并将上述议案提交公司董事会审议。 2 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-014 北京佰仁医疗科技股份有限公司 关于召开2024年度暨2025年第一季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 北京佰仁医疗科技股份有限公司（以下简称"公司"）已于2025年4月25日发布 公司2024年年度报告、2025年第一季度报告，为便于广大投资者更全面深入地了解 公司2024年度及2025年第一季度经营成果、财务状况，公司计划于2025年5月12日 （星期一）上午10:00-11:00举行2024年度暨2025年第一季度业绩说明会，就投资者 关心的问题进行交流。 一、说明会类型 会议召开时间：2025 年 5 月 12 日（星期一）上午 10:00-11:00 会 议 召 开 地 点 ： 上 海 证 券 交 易 所 上 证 路 演 中 心 （ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2025 年 5 月 5 日（星期一）至 5 ...

致同会计师事务所（特殊普通合伙）（以下简称"致同所"）成立于1981年（工 商登记日期：2011年12月22日），注册地址为北京市朝阳区建国门外大街22号赛特 广场五层，拥有财政部颁发的会计师事务所执业证书。 截至2024年年末，致同所从业人员近六千人，其中合伙人数量为239人，首席合 伙人为李惠琦先生；拥有执业注册会计师1,359人，其中签署过证券服务业务审计报 告的注册会计师超过400人。致同所2023年度业务收入人民币27.03亿元，其中，审计 业务收入人民币22.05亿元（含证券业务收入人民币5.02亿元）。致同所2023年度上 市公司（含A、B股）年报审计客户共计257家，收费总额人民币3.55亿元。这些上市 公司主要行业涉及制造业，信息传输、软件和信息技术服务业，批发和零售业，电 力、热力、燃气及水生产供应业，交通运输、仓储和邮政业等多个行业；本公司同 行业上市公司审计客户13家。 北京佰仁医疗科技股份有限公司董事会审计委员会 对会计师事务所2024年度履行监督职责情况的报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等 ...

证券代码：688198 证券简称：佰仁医疗 公告编号：2025-011 北京佰仁医疗科技股份有限公司 2024年度募集资金存放与实际使用情况专项报告 元，使用超募资金永久补充流动资金 1,600.00 万元。截至 2021 年 12 月 31 日，公司 募集资金累计使用 24,072.41 万元，尚未使用的募集资金专户余额为 28,617.60 万元（其 中募集资金 26,524.63 万元，专户存储累计利息扣除手续费 1,787.67 万元，自筹资金预 先支付的发行费金额 305.30 万元）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 经中国证券监督管理委员会《关于同意北京佰仁医疗科技股份有限公司首次公开 发行股票注册的批复》（证监许可〔2019〕2225 号）同意注册，北京佰仁医疗科技股 份有限公司（以下简称"公司"）向社会公开发行人民币普通股 2,400 万股，每股面值 人民币 1 元，每股发行价为人民币 23.68 元，应募集资金人民币 56,83 ...

北京佰仁医疗科技股份有限公司 对会计师事务所2024年度履职情况评估报告 北京佰仁医疗科技股份有限公司（以下简称"公司"）聘请致同会计师事务所（特殊 普通合伙）（以下简称"致同所"）作为公司 2024 年度财务报告审计机构及内部控制审 计机构。 根据财政部、国务院国有资产监督管理委员会、中国证券监督管理委员会颁布的 《国有企业、上市公司选聘会计师事务所管理办法》，公司对致同所 2024 年审计工作 的履职情况进行了评估。经评估，公司认为，致同所在资质等方面合规有效，履职能 够保持独立性，勤勉尽责，公允表达意见。具体情况如下： 一、会计师事务所基本情况 （一）基本信息 致同所成立于 1981 年（工商登记日期：2011 年 12 月 22 日），注册地址为北京市 朝阳区建国门外大街 22 号赛特广场五层，拥有财政部颁发的会计师事务所执业证书。 截至 2024 年年末，致同所从业人员近六千人，其中合伙人数量为 239 人，首席合 伙人为李惠琦先生；拥有执业注册会计师 1,359 人，其中签署过证券服务业务审计报告 的注册会计师超过 400 人。 致同所 2023 年度业务收入人民币 27.03 亿元，其中，审计业 ...